Skip to main content
. 2020 May 15;17(2):418–432. doi: 10.20892/j.issn.2095-3941.2019.0215

Figure 1.

Figure 1

High concentration of bevacizumab (100 μg/mL) enhances migration and tube formation of HUVECs in vitro. (A) Typical images of migrating HUVECs treated with bevacizumab under hypoxia conditions (hypoxia: O2 < 1%, 5% CO2, 94% N2; control: bevacizumab 0 μg/mL; bev10: bevacizumab 10 μg/mL, bev100: bevacizumab 100 μg/mL; normoxia: normal oxygen vehicle: 21% O2, 5% CO2, 74% N2); magnification, ×100. (B) Images of canal-like tubules formed by HUVECs treated with bevacizumab under hypoxia; magnification, ×50. (C) Quantitative analysis of migrating HUVECs treated with different doses of bevacizumab under hypoxia. Data represent mean ± SD of three independent experiments; *P < 0.05; one-way ANOVA. (D) Average total branching lengths of canal-like tubules formed by HUVECs treated with bevacizumab under hypoxia. Data represent mean ± SD, *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA.